%0 Journal Article
%T Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer.
%A Shore N
%A Pieczonka C
%A Heron S
%A Gazi M
%A Cahn D
%A Belkoff LH
%A Berger A
%A Mazzarella B
%A Veys J
%A Idom C
%A Morris D
%A Jayram G
%A Engelman A
%A Dato P
%A Bevan-Thomas R
%A Wise DR
%A Hardwick MK
%A Rojahn S
%A Layman P
%A Heald B
%A Ellsworth RE
%A Hatchell KE
%A Nussbaum RL
%A Nielsen SM
%A Esplin ED
%J J Urol
%V 0
%N 0
%D 2024 Aug 9
%M 39121056
%F 7.6
%R 10.1097/JU.0000000000004190
%X <B>UNASSIGNED: </B>Identification of pathogenic germline variants in patients with prostate cancer can help inform treatment selection, screening for secondary malignancies, and cascade testing. Limited real-world data are available on clinician recommendations following germline genetic testing in patients with prostate cancer.<BR><B>UNASSIGNED: </B>Patient data and clinician recommendations were collected from unselected patients with prostate cancer who underwent germline testing through the PROCLAIM trial. Differences among groups of patients were determined by 2-tailed Fisher's exact test with significance set at P < .05. Logistic regression was performed to assess the influence of test results in clinical decision-making while controlling for time of diagnosis (newly vs previously diagnosed).<BR><B>UNASSIGNED: </B>Among 982 patients, 100 (10%) were positive (>1 pathogenic germline variant), 482 (49%) had uncertain results (>1 variant of uncertain significance), and 400 (41%) were negative. Patients with positive results were significantly more likely than those with negative or uncertain results to receive recommendations for treatment changes (18% vs 1.4%, P < .001), follow-up changes (64% vs 11%, P < .001), and cascade testing (71% vs 5.4%, P < .001). Logistic regression demonstrated that positive and uncertain results were significantly associated with both changes to treatment and follow-up (P < .001) when controlling for new or previous diagnosis.<BR><B>UNASSIGNED: </B>Germline genetic testing results informed clinical recommendations for patients with prostate cancer, especially in patients with positive results. Higher than anticipated rates of clinical management changes in patients with uncertain results highlight the need for increased genetic education of clinicians treating patients with prostate cancer.